2015 Annual Report

PIQ Annual Report 2015


2015 Financial Reports

PIQ Half Year Report Appendix 4D (December)

PIQ Quarterly Report Appendix 4C (September)

PIQ Preliminary Final Report Appendix 4E (August)

PIQ Quarterly Report Appendix 4C (July)



Entitlement Issue Prospectus

Proteomics International Laboratories Ltd (PIQ) announced on 11 September 2015 a pro-rata non-renounceable entitlement issue to shareholders of approximately 12,645,363 options (exercisable at $0.20 each and expiring 31 March 2018) at an issue price of $0.01 each (Options) to raise up to approximately $126,454, before costs (Entitlement Issue or Offer).

The issue was proposed in the IPO Prospectus as a “loyalty option” for those Shareholders who held their issued shares or new shareholders supporting the Company in its first few months after listing. The Offer is underwritten by K S Capital Pty Limited (Underwriter). K S Capital Pty Limited is also lead manager under the Offer.

The Entitlement Issue will be offered to shareholders registered at the Record Date of 5:00 pm AWST on 18 September 2015 (Entitlement Record Date) with a registered address in Australia or New Zealand (Eligible Shareholders) on the basis of one (1) Option for every four (4) Shares held.

To access these documents please read the information below and follow the instructions.


This is an important document that should be read in it’s entirety. If you do not understand it, please consult your professional adviser.

Lodgement of Prospectus with the ASIC

The electronic Entitlement Issue Prospectus accessible through this web page has been lodged with the Australian Securities and Investments Commission (ASIC).

An application for Options under the Offer may only be made by Eligible Shareholders registered at the Entitlement Record Date.

The information and electronic Prospectus provided by this web page has been verified by Australian regulatory authorities for Australian investors only, but not for other jurisdictions. This Prospectus does not constitute an offer of securities in any jurisdiction where, or to any person to whom, it would not be lawful to issue the Prospectus or make the offer. It is the responsibility of any applicant outside Australia to ensure compliance with all laws of any country relevant to their applications, and any such applicant should consult their professional advisers as to whether any government or other consents are required, or whether any formalities need to be observed to enable them to apply for and be allotted any securities.

No action has been taken to register or qualify the Options or the Offer or otherwise to permit a public offering of the securities in any jurisdiction outside Australia.

For more details on the Entitlement Issue Offer please contact:

Karen Logan
Company Secretary, Proteomics International Laboratories Ltd
Tel: +61 8 9389 1992
Email: enquiries@proteomicsinternational.com

or, the Underwriter and Lead Manager to the Entitlement Issue Offer: KS Capital Pty Ltd
Gregory Wood
Managing Director
Tel: +61 2 8005 1091
Mobile: 0416 076 377
Email: g.wood@kscapital.com.au

If you would like a hard copy of the Entitlement Issue Prospectus please send a request to prospectus@proteomicsinternational.com


  • This field is for validation purposes and should be left unchanged.